QURE - NASDAQ

uniQure N.V.

QURE·NASDAQ

$29.88

+12%

HealthcareBiotechnology

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.88B

EPS-3.4600

P/E Ratio-8.64

Earnings Date08/04/2026

824.91M

Assets

48%

3Y+17.0%

5Y+142.0%

10Y+334.0%

626.01M

Total Liabilities

11%

3Y+173.0%

5Y+549.0%

10Y+394.0%

198.90M

Total Equity

-3046%

3Y-58.0%

5Y-18.0%

10Y+213.0%

uniQure N.V. Funding & Solvency Profile

QURE · NASDAQ

Current Assets

Cash & Cash Equivalents80.24M

Net Receivables12.94M

Inventory0.00

Other Current Assets20.51M

Total Current Assets656 M

Non-Current Assets

Property, Plant & Equipment26.32M

Goodwill & Intangible Assets98.14M

Long-Term Investments30.24M

Other Non-Current Assets5.56M

Total Non-Current Assets62 M

Total Assets

824.91M

Financial Health Analysis

Current Ratio

10.43x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

3.15x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

593 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

80% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

uniQure N.V. Balance Sheet

QURE • NASDAQ

uniQure N.V. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	80.2M	158.9M	241.4M	228M	556.3M	244.9M	377.8M	234.9M	159.4M	132.5M	222.5M	64.7M	32.9M	347.8K	1.4M	23.8M
Short-Term Investments	542.3M	208.6M	376.5M	124.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	622.5M	367.5M	617.9M	352.8M	556.3M	244.9M	377.8M	234.9M	159.4M	132.5M	222.5M	64.7M	32.9M	347.8K	1.4M	23.8M
Net Receivables	12.9M	5.9M	4.2M	102.4M	58.8M	6.6M	947K	233K	1.6M	9.2M	4.1M	4.2M	3.6M	1.1M	1.4M	853.8K
Accounts Receivables	12.9M	5.9M	4.2M	102.4M	58.8M	6.6M	947K	233K	1.6M	9.2M	4.1M	3M	2M	34.4K	45.4K	46.5K
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6M	1.1M	1.4M	807.3K
Inventory	0.0	0.0	12M	6.9M	0.0	0.0	0.0	1.1M	1.1M	996K	475.6K	243.2K	1.2M	-1.1M	0.0	0.0
Prepaids	0.0	9.3M	15.1M	11.8M	10.5M	4.3M	4.7M	1.1M	1.1M	996K	690K	623.2K	539.9K	0.0	0.0	0.0
Other Current Assets	20.5M	7.6M	2.7M	2.8M	2.7M	3M	-4M	329K	687K	1.3M	1.2M	321.7K	3M	0.0	0.0	0.0
Total Current Assets	656M	390.3M	651.9M	476.8M	628.2M	258.9M	384.2M	236.6M	162.8M	143.9M	229M	69.8M	38.2M	1.5M	2.8M	24.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	26.3M	34.1M	75.3M	83.3M	69.1M	58.4M	55.6M	29.2M	34.3M	35.7M	26M	23.9M	3.6M	1.6M	1.2M	1.7M
Goodwill	25.4M	22.4M	26.4M	25.6M	27.6M	542K	496K	506K	530K	465K	483.2K	1.6M	0.0	0.0	0.0	0.0
Intangible Assets	72.8M	71M	60.5M	58.8M	62.7M	3.4M	5.4M	5.2M	8.8M	8.3M	7.9M	19.9M	10.7M	4.3M	3.5M	3.9M
Goodwill & Intangible Assets	98.1M	93.5M	86.9M	84.4M	90.3M	3.9M	5.9M	5.7M	9.3M	8.8M	8.4M	21.5M	10.7M	4.3M	3.5M	3.9M
Long-Term Investments	30.2M	27.5M	2.2M	40M	0.0	2.7M	2.9M	2.4M	2.5M	1.8M	1.2M	0.0	0.0	0.0	0.0	0.0
Tax Assets	8.7M	9.9M	12.3M	14.5M	15.6M	16.4M	-2.9M	-2.4M	-2.5M	-1.8M	-1.2M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	5.6M	1.4M	3.2M	6.1M	5.9M	0.0	2.9M	2.4M	2.5M	1.8M	1.2M	1.2M	1.3M	0.0	0.0	0.0
Total Non-Current Assets	168.9M	166.2M	179.8M	228.2M	180.9M	81.5M	64.4M	37.3M	46.1M	46.3M	35.7M	46.7M	15.6M	5.9M	4.7M	5.6M
Total Assets	824.9M	556.5M	831.7M	705M	809.2M	340.4M	448.6M	273.9M	208.9M	190.3M	264.7M	116.5M	53.8M	7.4M	7.5M	30.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.2M	7.2M	6.6M	11M	2.5M	3.8M	5.7M	3.8M	2.9M	5.5M	4.1M	5.9M	4.8M	2.8M	2.3M	2.3M
Accounts Payable	5.2M	7.2M	6.6M	11M	2.5M	3.8M	5.7M	3.8M	2.9M	5.5M	4.1M	3.9M	4.8M	759.8K	2.3M	2.1M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2M	0.0	2M	3.6K	260.7K
Accrued Expenses	0.0	10.1M	12.8M	17.2M	12.6M	7.7M	12.5M	7.7M	8M	9.4M	7M	0.0	0.0	0.0	0.0	0.0
Short Term Debt	3.9M	0.0	0.0	8.4M	5.8M	5.5M	0.0	0.0	1.1M	605K	5.6M	829.3K	1.2M	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	3.6M	8.3M	0.0	0.0	0.0	5.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2M	881.2K	1.2M	1.1M	201K	924.1K	260.7K
Deferred Revenue	0.0	0.0	0.0	11.1M	13M	2.1M	7.6M	7.6M	4.6M	6.1M	6.8M	1.6M	1.8M	0.0	0.0	0.0
Other Current Liabilities	53.9M	19.1M	45.9M	28.2M	2.9M	8.3M	0.0	856K	2.7M	1.1M	10.3M	6.6M	6.7M	4.6M	2.5M	3.3M
Total Current Liabilities	62.9M	40.1M	73.7M	75.9M	36.8M	27.3M	31.6M	20M	19.3M	22.7M	26.7M	14.9M	14.4M	7.4M	4.8M	5.6M
NON-CURRENT LIABILITIES
Long Term Debt	522.9M	51.3M	101.7M	102.8M	101M	35.6M	36.1M	35.5M	19.7M	19.6M	14.6M	20M	8.7M	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	23.1M	28.9M	67.4M	75.6M	82.9M	18.7M	21.7M	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	8M	7M	7.5M	8.3M	12.9M	0.0	0.0	9.6M	10.4M	6.8M	6.9M	1.7M	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	22.4M	453.7M	412.7M	10.3M	33.8M	3.1M	3.6M	10M	13.9M	8.7M	85.9M	8.4M	-7.8M	0.0	5.9M	6.1M
Total Non-Current Liabilities	563.1M	523.2M	550.3M	153M	176.6M	69.2M	93.9M	74.3M	99.6M	103.9M	107.4M	49.2M	31.7M	595.1K	6.1M	6.4M
Capital Lease Obligations	9.8M	14.7M	36.7M	31.7M	29M	30.4M	37M	0.0	0.0	0.0	0.0	162.9K	417K	595.1K	233.3K	293.9K
Total Liabilities	626M	563.3M	624M	229M	213.4M	96.5M	125.6M	94.3M	118.9M	126.6M	134.1M	64.1M	46.1M	8M	10.9M	12M
SHAREHOLDERS' EQUITY
Common Stock	3.7M	2.9M	2.9M	2.8M	2.8M	2.7M	2.7M	2.3M	1.9M	1.6M	1.3M	1.1M	842.3K	638.8K	307.2K	312.5K
Additional Paid-In Capital	1.6B	1.2B	1.1B	1.1B	1.1B	1B	986.8M	720.1M	566.5M	464.7M	374.6M	250.6M	196.2M	151.8M	129.5M	132.8M
Retained Earnings	-1.3B	-1.1B	-890.4M	-581.9M	-455.1M	-784.7M	-659.7M	-535.5M	-467.1M	-396.1M	-276.1M	-220.2M	-198.9M	-155M	-136.7M	-117.3M
Accumulated Other Comprehensive Income/Loss	-58.2M	-52.8M	-53.6M	-58.3M	-28.9M	9.9M	-6.7M	-7.3M	39.1M	-6.6M	28.5M	20.9M	9M	2M	3.5M	2.4M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	81.3M	0.0	9.9M	0.0	217.1K	0.0
Total Stockholders' Equity	198.9M	-6.8M	207.7M	476M	595.8M	243.9M	323.1M	179.6M	89.9M	63.6M	130.6M	52.4M	7.7M	-592.5K	-3.4M	18.2M
Total Equity	198.9M	-6.8M	207.7M	476M	595.8M	243.9M	323.1M	179.6M	89.9M	63.6M	130.6M	52.4M	7.7M	-592.5K	-3.4M	18.2M
SUMMARY
Total Liabilities & Equity	824.9M	556.5M	831.7M	705M	809.2M	340.4M	448.6M	273.9M	208.9M	190.3M	264.7M	116.5M	53.8M	7.4M	7.5M	30.2M
Total Investments	572.5M	236.1M	378.7M	164.8M	0.0	2.7M	2.9M	2.4M	2.5M	1.8M	1.2M	0.0	0.0	0.0	0.0	0.0
Total Debt	536.6M	66.1M	138.4M	142.9M	135.7M	71.5M	73.1M	35.5M	20.2M	20.2M	21.2M	21M	11.2M	595.1K	233.3K	293.9K
Net Debt	456.4M	-92.9M	-103M	-85.1M	-420.5M	-173.4M	-304.7M	-199.4M	-139.2M	-112.3M	-201.3M	-43.8M	-21.7M	247.3K	-1.2M	-23.5M
Shares Outstanding	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400	62,529,400

SEC Filings

QURE - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 05, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 27, 2026	June 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 02, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 09, 2026	January 09, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 04, 2025	December 04, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing

Showing 1 to 10 of 255 filings

Related Guides

Blog Categories

Continue your QURE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.